Cargando…

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology()

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the world's population. Immunobiological medications are prescribed for certain patients with severe forms of psoriasis, however, these drugs increase the risk of reactivation of viral diseases such as hepatit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steglich, Raquel Bissacotti, Meneghello, Luana Pizarro, de Carvalho, André Vicente Esteves, Cheinquer, Hugo, Muller, Fernanda Melo, Reginatto, Flávia Pereira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148283/ https://www.ncbi.nlm.nih.gov/pubmed/25054756 http://dx.doi.org/10.1590/abd1806-4841.20143013

Ejemplares similares

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Case series: psoriasis in solid organ transplant patients and immunobiological agents()
por: Meneghello, Luana Pizarro, et al.
Publicado: (2023)

Psoriasis comorbidities: complications and benefits of immunobiological treatment
por: de Carvalho, André Vicente Esteves, et al.
Publicado: (2016)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Dermoscopic clues in the diagnosis of amelanotic and hypomelanotic malignant melanoma()
por: Steglich, Raquel Bissacotti, et al.
Publicado: (2012)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Do you know this syndrome?()
por: Frainer, Renata Hubner, et al.
Publicado: (2013)

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
por: Garcia-Valladares, Ignacio, et al.
Publicado: (2011)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis
por: Krulig, Eliana, et al.
Publicado: (2010)

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
por: Hermanns-Lê, Trinh, et al.
Publicado: (2012)

Influence of ustekinumab on body weight of patients with psoriasis: an initial report
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2014)

Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases
por: Kim, Ye Seul, et al.
Publicado: (2016)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
por: Avgerinou, Georgia, et al.
Publicado: (2012)

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
por: Jayasekera, Prativa S., et al.
Publicado: (2016)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
por: Brummer, Grace C., et al.
Publicado: (2017)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Ustekinumab Biotherapy and Real-Time Psoriasis Capacitance Mapping: A Pilot Study
por: Piérard-Franchimont, Claudine, et al.
Publicado: (2012)

Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis
por: Kapoor, Shailendra
Publicado: (2012)

Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
por: Zhao, Yue, et al.
Publicado: (2014)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
por: Elkady, Amal, et al.
Publicado: (2017)

Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab
por: Hsiao, Chuan-Yu, et al.
Publicado: (2017)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
por: Petty, Amy J., et al.
Publicado: (2020)

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis
por: Charakopoulos, Emmanouil, et al.
Publicado: (2020)

Real-world use of ustekinumab therapeutic drug monitoring in moderate to severe psoriasis
por: Elberdín, Laida, et al.
Publicado: (2022)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_65r61h0rrf023f5m64qo1na5ef